Efficacy and safety of nasal high-flow oxygen in COPD patients.
- Vogelsinger H Pneumology, Internal Medicine II, Department of Internal Medicine, Medical University of Innsbruck, Innsbruck, Austria.
- Halank M Pneumology, Medical Clinic and Polyclinic, University Hospital Carl Gustav Carus, Dresden, Germany.
- Braun S Pneumology, Medical Clinic and Polyclinic, University Hospital Carl Gustav Carus, Dresden, Germany.
- Wilkens H Pneumology, Saarland University Medical Centre, Homburg, Germany.
- Geiser T Department for Pulmonary Medicine, University Hospital Inselspital, Bern, Switzerland.
- Ott S Department for Pulmonary Medicine, University Hospital Inselspital, Bern, Switzerland.
- Stucki A Pneumology, Berner REHA Zentrum Heiligenschwendi, Heiligenschwendi, Switzerland.
- Kaehler CM Pneumology, Internal Medicine II, Department of Internal Medicine, Medical University of Innsbruck, Innsbruck, Austria. c.m.kaehler@i-med.ac.at.
- 2017-11-19
Published in:
- BMC pulmonary medicine. - 2017
COPD.
High-flow oxygen
hypercapnic.
normocapnic.
short-term nasal highflow.
Aged
Aged, 80 and over
Cannula
Female
Humans
Hypercapnia
Hypoxia
Male
Middle Aged
Oxygen
Oxygen Inhalation Therapy
Partial Pressure
Prospective Studies
Pulmonary Disease, Chronic Obstructive
Residual Volume
English
BACKGROUND
Nasal high-flow oxygen therapy (HFOT) is a novel treatment option for patients suffering from acute or chronic respiratory failure. Aim of our study was to compare safety and efficacy of HFOT with those of conventional oxygen treatment (COT) in normo- and hypercapnic COPD patients.
METHODS
A single cohort of 77 clinically stable hypoxemic patients with an indication for long-term oxygen treatment (LTOT) with or without hypercapnia successively received COT and HFOT for 60 min each, including oxygen adaption and separated by a 30 min washout phase.
RESULTS
HFOT was well-tolerated in all patients. A significant decrease in PaCO2 was observed during oxygen adaption of HFOT, and increased PaO2 coincided with significantly increased SpO2 and decreased AaDO2 during both treatment phases. Even at a flow rate of 15 L/min, oxygen requirement delivered as air mixture by HFOT tended to be lower than that of COT (2.2 L/min). Not only was no increase in static or dynamic lung volumes observed during HFOT, but even was a significant reduction of residual lung volume measured in 36 patients (28%).
CONCLUSIONS
Thus, short-term use of HFOT is safe in both normocapnic and hypercapnic COPD patients. Lower oxygen levels were effective in correcting hypoxemic respiratory failure and reducing hypercapnia, leading to a reduced amount of oxygen consumption. Long-term studies are needed to assess safety, tolerability, and clinical efficacy of HFOT.
TRIAL REGISTRATION
ClinicalTrials.gov NCT01686893 13.09.2012 retrospectively registered (STIT-1) and NCT01693146 14.09.2012 retrospectively registered (STIT-2). Studies were approved by the local ethics committee (Ethikkommission der Medizinischen Universität Innsbruck, Studienkennzahl UN3547, Sitzungsnummer 274/4.19).
Nasal high-flow oxygen therapy (HFOT) is a novel treatment option for patients suffering from acute or chronic respiratory failure. Aim of our study was to compare safety and efficacy of HFOT with those of conventional oxygen treatment (COT) in normo- and hypercapnic COPD patients.
METHODS
A single cohort of 77 clinically stable hypoxemic patients with an indication for long-term oxygen treatment (LTOT) with or without hypercapnia successively received COT and HFOT for 60 min each, including oxygen adaption and separated by a 30 min washout phase.
RESULTS
HFOT was well-tolerated in all patients. A significant decrease in PaCO2 was observed during oxygen adaption of HFOT, and increased PaO2 coincided with significantly increased SpO2 and decreased AaDO2 during both treatment phases. Even at a flow rate of 15 L/min, oxygen requirement delivered as air mixture by HFOT tended to be lower than that of COT (2.2 L/min). Not only was no increase in static or dynamic lung volumes observed during HFOT, but even was a significant reduction of residual lung volume measured in 36 patients (28%).
CONCLUSIONS
Thus, short-term use of HFOT is safe in both normocapnic and hypercapnic COPD patients. Lower oxygen levels were effective in correcting hypoxemic respiratory failure and reducing hypercapnia, leading to a reduced amount of oxygen consumption. Long-term studies are needed to assess safety, tolerability, and clinical efficacy of HFOT.
TRIAL REGISTRATION
ClinicalTrials.gov NCT01686893 13.09.2012 retrospectively registered (STIT-1) and NCT01693146 14.09.2012 retrospectively registered (STIT-2). Studies were approved by the local ethics committee (Ethikkommission der Medizinischen Universität Innsbruck, Studienkennzahl UN3547, Sitzungsnummer 274/4.19).
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1186/s12890-017-0486-3
- PMID 29149867
- Persistent URL
- https://folia.unifr.ch/global/documents/178046
Statistics
Document views: 13
File downloads:
- fulltext.pdf: 0